Drugs and patents in ATC class J01EE - Combinations of sulfonamides and trimethoprim, incl. derivatives

Subscribe to access the full database, or Start Trial
Tradename	Generic Name
BACTRIM	sulfamethoxazole; trimethoprim
SEPTRA	sulfamethoxazole; trimethoprim
SULFAMETHOXAZOLE AND TRIMETHOPRIM	sulfamethoxazole; trimethoprim
BACTRIM PEDIATRIC	sulfamethoxazole; trimethoprim
SEPTRA GRAPE	sulfamethoxazole; trimethoprim
>Tradename	>Generic Name

Last updated: June 24, 2026

ATC J01EE “combinations of sulfonamides and trimethoprim” centers on a small set of pharmacy and hospital anchor products, led by fixed-dose trimethoprim-sulfamethoxazole (TMP-SMX). Patent estates for J01EE are typically built around (i) API(s) and early-process filings, (ii) product form and manufacturing changes, and (iii) line extensions such as pediatric suspensions, IV formulations, or specialty combinations. In most major markets, first-generation product exclusivity has largely lapsed, shifting the competitive battleground to formulation and method patents, ANDA paragraph IV challenges, and enforceability against “non-infringing design-around” substitutes.

Because J01EE is a therapeutic class rather than a single brand, market dynamics are driven by (1) how payers structure antibiotic reimbursement, (2) hospital formulary preferences for IV vs oral, (3) public procurement tendering, and (4) tolerance for taste, suspension stability, and dosing adherence in pediatrics. Patent value concentrates in the small number of remaining branded dosage forms that still have enforceable formulation or use patents.

What patents protect ATC J01EE (sulfamethoxazole and trimethoprim) combinations?

Which active ingredient pairs define J01EE

J01EE is the fixed combination space of sulfonamides plus trimethoprim. The commercial “workhorse” is TMP-SMX using:

Trimethoprim + sulfamethoxazole (most common, includes oral tablets, pediatric suspension, IV where approved).

Derivative coverage can include:

Alternative salts/grades of components
Different fixed ratios (where approved)
Extended-release or pediatric-friendly presentations
Alternative manufacturing processes that improve stability or bioavailability

Patent estate pattern for TMP-SMX (what typically remains enforceable)

For TMP-SMX combinations, the practical patent landscape in the post-2010 era is usually dominated by:

Formulation patents: particle size control, excipient systems for suspensions, stabilized blends, moisture/oxidation control, or IV concentration/solvent compositions.
Manufacturing and process patents: sterilization and aseptic processing approaches, blending granulation and drying conditions, or control strategies for uniformity.
Method-of-use patents: dosing regimens, prophylaxis windows, or specific clinical indications (less common as independent pillars compared with formulation).
Polymorph/solid-state patents: rare for legacy TMP-SMX solids unless specific drug substances were re-developed or re-crystallized.

Bottom line: for J01EE, the enforceable “edge” tends to be product-specific, not class-wide. Most generics can enter with label-equivalent TMP-SMX unless they run into formulation-specific patents tied to a particular dosage form or stability profile.

When does TMP-SMX lose exclusivity in the US, EU, and key markets?

US exclusivity vs patent expiry: how the timeline plays out

In the US, “exclusivity” can mean:

Orange Book patent protection for specific listed patents
FDA exclusivities tied to pediatric, orphan, new clinical investigations, or 505(b)(2) approvals

For legacy TMP-SMX, Orange Book protection often ends first because patents from the original fixed-combination era expire. Remaining barriers (if any) are usually:

Product-specific formulation patents listed for a branded NDA/ANDA-holder
Process patents asserted against a particular manufacturer’s manufacturing line

EU SPC and national rights: typical outcomes

EU market exclusivity in this class typically hinges on:

Whether any later “second medical use” or formulation is eligible for an SPC (often unlikely for generic TMP-SMX core actives unless a qualifying authorization and patent pair exist).
National pediatric extension mechanisms or local marketing exclusivity.

Featured snippet answer

Most TMP-SMX combination products in major markets have already passed primary patent exclusivity for the core fixed combination. The remaining exclusivity timeline risk is mostly formulation- and product-specific rather than class-wide.

What is the Orange Book status of TMP-SMX combinations in the US?

Orange Book logic for J01EE

For a given branded TMP-SMX product, Orange Book entries usually include:

Drug substance patents (sulfamethoxazole or trimethoprim composition and/or salts)
Drug product patents (formulation and/or manufacturing process)
Sometimes method-of-use patents tied to specific claims

How Orange Book listings translate into generic entry barriers

A generic ANDA filer faces:

Infringement risk if their generic product practices the same formulation or manufacturing steps claimed
Potential “carve-out” if they can demonstrate non-infringement or invalidity
Paragraph IV settlement probability if the branded holder has enforceable patents with remaining term or if litigation cost is material

Bottom line: the Orange Book is the gating layer. For J01EE, the most important question is not whether TMP-SMX can be made, but which branded presentations still have listed patents with unexpired or recently expiring claims.

Which companies dominate J01EE TMP-SMX markets, and what are the licensing and supply dynamics?

Market structure

J01EE is shaped by:

Multiple generic manufacturers producing TMP-SMX tablets and suspensions
A smaller number of brands with unique formulations or specific IV presentations
Hospital procurement cycles that shift market share based on tender pricing and supply reliability

Why supply chain matters

TMP-SMX uses well-established APIs, so supply is less constrained by molecule synthesis and more constrained by:

Quality system throughput
Suspension stability and packaging formats
IV concentrate aseptic production capacity where applicable

Licensing model

In J01EE, licensing tends to cluster around:

Formulation know-how and manufacturing control packages
Exclusive distribution rights for specialty pediatric or IV formats
Cross-licensing where later 505(b)(2) approvals rely on reference product formulations

Net effect: licensing can extend commercial advantage even after core patents expire, because market access is tied to practical production differentiation and regulatory positioning.

What generic entry risks exist for TMP-SMX combinations, including Paragraph IV challenges?

Paragraph IV risk map: where challenges concentrate

For J01EE, paragraph IV challenges typically target:

Drug product formulation patents listed for a branded pediatric suspension or specialty dosage form
Process patents covering manufacturing steps that affect impurity profile, dissolution, or stability

Non-infringement and design-around pathways

Generic developers usually attempt:

Excipient system differences that avoid literal infringement
Manufacturing parameter changes that affect whether a process claim is met
Alternative particle-size specifications where allowed
Changing scale or process order to avoid “step-combination” limitations

Settlement dynamics

Where a branded holder has a realistic enforcement pathway (clear claim scope, active sales tied to the patented product), paragraph IV challenges often result in:

Shared-launch settlements
Carve-outs by dosage form strength and packaging
License-and-supply structures that preserve margin for the branded product line

Bottom line: generic entry is usually less risky for oral solid dosage strengths once core patents expire. Suspension stability and IV formulations are the areas where residual patent protection often has the most traction.

How do biosimilar or biologics risks apply to ATC J01EE?

J01EE is not a biologics space. It is a small-molecule fixed combination. Biosimilar risk is not a relevant competitive factor. Patent risk remains within:

Small molecule formulation and process patents
Method-of-use patents (if any)
Regulatory exclusivity specific to a presentation or approved reference pathway

What formulations are protected in J01EE, and how do they affect market competition?

Protected formulation themes for TMP-SMX

In practice, patents frequently protect:

Suspension formulations: viscosity, suspending agents, preservatives, pH range, taste-masking systems, and stability against precipitation.
Tablets/capsules: granulation method and dissolution rate targets, coating systems, and impurity controls.
IV products (where applicable): solvent system, concentration, osmolarity targets, and stability under storage conditions.

Why formulation patents are commercially important

Even if the actives are off-patent, the branded product can keep share if:

The patented formulation produces a clinically acceptable bioequivalence profile and fewer administration issues
The market values pediatric adherence and shelf-life
Procurement prefers fewer stock-keeping units (SKUs) with stable supply

Bottom line: formulation patents act as “product moat” in J01EE, especially in pediatric and IV segments.

What method-of-use patents cover TMP-SMX combinations?

Method-of-use patents in antimicrobial fixed combinations are not the dominant patent type historically, but they can still appear as:

Indication-specific claims (certain infection types, prophylaxis)
Dosing schedule claims
Patient population stratification claims

Enforceability tends to be sensitive to:

Prior art and obviousness
Clinical endpoint support
Indefiniteness and claim breadth

Bottom line: method-of-use claims can create litigation risk, but in J01EE the practical moat is more often formulation tied to an approved product presentation.

Which patent litigation affects TMP-SMX combinations, and what settlement patterns are typical?

Litigation pattern for J01EE

When litigation exists, it typically involves:

ANDA paragraph IV suits targeting Orange Book-listed formulation or process patents
Disputes over claim construction, infringement mapping to the generic’s manufacturing and composition data
Invalidity defenses based on prior art and obviousness

Settlement patterns that matter

Settlements in small-molecule combination categories generally align with:

Launch date carve-outs
Market segmentation by dosage strength or dosage form
Payment-for-delay risk controls under US law, but settlements can still preserve branded share through design-around constraints

Bottom line: litigation is usually product-specific, and the most important variable is whether the branded holder has a short list of strong patents still linked to commercial sales.

How does ATC J01EE compare with other antibiotic combination classes in patent durability?

Durability comparison: what differs

Compared with newer antibiotic combinations with biologics-adjacent patents, J01EE generally has:

Longer history of generic competition
Core active ingredients widely synthesized and well prior-art
Patent claims concentrated on incremental formulation and process improvements

Other combination antibiotic classes can have:

Higher share of novel chemical entities, which extends core patent life
More frequent new clinical development programs

Bottom line: J01EE is typically a “late-stage patent” category where durability comes from formulation packaging and stability rather than new mechanism claims.

Which jurisdictions matter most for J01EE patent value and enforcement?

Key enforcement geographies

United States: Orange Book listing and ANDA litigation is the main enforcement vector.
European Union / UK: patent enforcement relies on national litigation with separate enforcement calendars; SPC is less common for legacy fixed combinations unless there is a qualifying eligible authorization.
Canada, Australia, Japan: similar enforcement logic, with local regulatory listings and patent linkage regimes shaping entry.
Emerging markets: enforcement is often less predictable, and tender pricing can dominate regardless of patent stance.

Bottom line: for high-stakes business decisions, US patent linkage and any remaining EU/UK patent enforcement are the most determinative for timing and generic entry risk.

Revenue exposure and pricing dynamics: what drives profitability in J01EE?

How pricing compresses patent value

TMP-SMX faces:

Rapid generic discounting once a dosage form clears patent hurdles
Procurement-led price competition
Low margin tolerance, making “small” patent wins commercially meaningful only if they delay generic penetration on high-volume SKUs

Where residual patent value can still show up

Residual value can exist when:

A branded pediatric suspension keeps shelf-life and handling advantages that payers still reimburse
A branded IV formulation reduces administration time and is preferred by hospitals
A particular manufacturer’s supply disruptions create temporary pricing power

Bottom line: patent value is tightly tied to whether the patented product remains a payer- and hospital-preferred SKU.

Key take: How strong is the patent estate for ATC J01EE, and where are the most likely remaining barriers?

Patent strength assessment framework

For J01EE, patent strength is strongest where:

Claims are clearly linked to an approved branded dosage form
The claim scope covers formulation components used in current commercial products
Manufacturing/process claims are supported by evidence that generic processes likely practice the claim

Patent strength is weakest where:

Claims read broadly on any TMP-SMX formulation (easy invalidity or design-around)
The claims are driven by late-stage secondary patents unaligned with actual commercial sales

Most likely remaining barriers

Pediatric suspension formulation stability patents
IV formulation and aseptic process patents where relevant
Specific drug product patents on impurity control and dissolution profile targets

Bottom line: in J01EE, the most important patents are those that protect a specific marketed dosage form rather than the fixed combination itself.

Key Takeaways

ATC J01EE is dominated by fixed-dose TMP-SMX combinations; in major markets, core actives are typically long off primary patent protection.
Patent value in J01EE concentrates in formulation and process patents tied to specific dosage forms, especially pediatric suspensions and any protected IV presentations.
Generic entry risk is largely a function of Orange Book listings tied to those dosage forms and the enforceability of drug product and process claims.
Litigation, when it occurs, most often follows paragraph IV challenges targeting formulation and manufacturing patents rather than class-wide active ingredient claims.
Commercial dynamics are procurement and payer-driven; patent-driven price premiums persist only if a patented product stays the preferred SKU.

FAQs

What are the most common patent claim types used to protect TMP-SMX suspensions?
How do paragraph IV challenges typically argue non-infringement for generic TMP-SMX?
Which TMP-SMX dosage forms tend to retain the most branded share after core patent expiry?
Do method-of-use patents for TMP-SMX materially delay generic competition compared with formulation patents?
How does hospital tendering change the commercial impact of patent expiration in J01EE?

References (APA)

No sources were cited because the request requires a specific, verifiable patent-and-regulatory dossier for J01EE individual products and those details were not provided.